These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32966350)

  • 21. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report.
    Qiu D; Zhang Y; Xue YB; Shen Q; Li H; Huang P; Hu JJ; Wang YS
    Thorac Cancer; 2019 Apr; 10(4):1023-1028. PubMed ID: 30775851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted/emerging therapies for metastatic non-small cell lung cancer.
    Horn L
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):676-8. PubMed ID: 25995428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
    Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
    Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging targeted therapies in non-small cell lung cancer.
    Khanal N; Ganti AK
    Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
    Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
    Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROS1-rearranged Non-small Cell Lung Cancer.
    Giustini NP; Bazhenova L
    Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
    Calvo V; Camps C; Carcereny E; Cobo M; Dómine M; García Campelo MR; González Larriba JL; Guirado M; Hernando-Trancho F; Massutí B; Nadal E; Rodríguez-Abreu D; Sánchez A; Sullivan IG; Provencio M;
    Clin Transl Oncol; 2024 Mar; 26(3):597-612. PubMed ID: 37651020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy of non-small cell lung cancer.
    Svaton M
    Klin Onkol; 2021; 34(Supplementum 1):48-52. PubMed ID: 34154330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [NSCLC and new oncogenic mutations: Diagnosis and perspectives].
    Basse C; Swalduz A; Mc Leer A; Moro-Sibilot D; Remon J; Girard N
    Rev Mal Respir; 2021 May; 38(5):477-488. PubMed ID: 34020835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
    J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
    Rosell R; Karachaliou N; Wolf J; Ou SH
    Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.